Clinical trials: Vasomotor Symptoms
Vasomotor Symptoms
Study Evaluating Safety, Tolerability, and PK of DVS SR in Healthy Japanese Women
Safety, tolerability, and pharmacokinetics (PK) of desvenlafaxine succinate sustained release (DVS SR) in healthy Japanese female subjects.
- Trial name
- NCT00397176
- Testing
- desvenlafaxine succinate sustained release (DVS SR)
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Healthy, Menopause
One Week Clinical Study in Subjects With Menopausal Symptoms
The goal of this clinical trial is to Examine the Benefits of an Oral Product in Subjects With Menopausal Symptoms. The main questions it aims to answer are: 1.
- Trial name
- NCT06794021
- Testing
- Dietary Supplement with Proprietary Herbal Extract Blend and GABA
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Olly, PBC
Menopausal Symptoms
Randomized Placebo Controlled Clinical Study of an Oral Product in Subjects With Menopausal Symptoms
The objective of this study is to assess the safety and effectiveness of a dietary supplement for symptom relief in subjects with menopausal symptoms over the course of five weeks of continuous daily use.
- Trial name
- NCT06787443
- Testing
- Dietary Supplement with Proprietary Herbal Extract Blend and GABA
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Olly, PBC
Vasomotor Symptoms
A Study to Investigate Relative Bioavailability, Safety and Tolerability of Single- and Multiple-doses of Elinzanetant in Healthy Female Participants
The aim of this study is to examine the relative bioavailability of elinzanetant when administered in new oral formulations (treatment B and C) after both single and multiple oral doses, compared to its administration in soft gel…
- Trial name
- NCT07229404
- Testing
- Treatment A, Treatment B, Treatment C
- Where
- Canada
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Bayer
Vasomotor Symptoms (VMS)
Safety and Efficacy Study of AR08 for the Treatment of Vasomotor Symptoms (VMS)
The purpose of this study is to determine the effective dose or dose range of AR08 in the treatment of VMS in menopausal females.
- Trial name
- NCT02049164
- Testing
- AR08
- Where
- 15 sites in United States
- Volunteers
- 32 people
- Sponsor
- Arbor Pharmaceuticals, Inc.
Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men
A Study to Learn How Safe Elinzanetant is, How it Affects the Body, and How it Moves Into, Through and Out of the Body After Single and Multiple Doses in Japanese Healthy Female Adults
Researchers are looking for a new way to treat women who have symptoms that are caused by the sex hormonal changes that happen when a woman's body is going through the menopause.
- Trial name
- NCT04981431
- Testing
- Elinzanetant (BAY3427080)
- Where
- Japan
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Bayer
Vasomotor Symptoms (VMS) Associated With Menopause
An Observational Study to Learn More About Vasomotor Symptoms Burden and Treatment Patterns in Menopausal Women Before and After Participating in OASIS Studies
This is an observational study to learn more about vasomotor symptoms (VSM) burden and treatment patterns in menopausal women before and after participating in OASIS studies.
- Trial name
- OASIS STAR (NCT06949553)
- Testing
- No study intervention
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bayer
Hot Flashes
A Clinical Trial to Demonstrate the Efficacy and Safety of Cenestin 0.3 mg for the Treatment of Hot Flashes
This is a randomized, double-blind study to compare the efficacy and safety of daily doses of Cenestin 0.3 mg tablets to placebo in reducing the frequency and severity of moderate to severe hot flashes in postmenopausal women.
- Trial name
- NCT00272935
- Testing
- Cenestin 0.3 mg Tablets
- Where
- 49 sites in United States
- Volunteers
- 400 people
- Sponsor
- Duramed Research
Menopause, Vasomotor; Syndrome
Efficacy of Nano-Pso Therapy in Menopause
Vasomotor syndrome is prevalent in 85% of postmenopausal women, hormone therapy in menopause is first-line therapy, but 38% of patients have some contraindication for its use.
- Trial name
- NCT06432816
- Testing
- NANO-PSO
- Where
- Mexico
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Distribuidora Biolife SA de CV
Vasomotor Symptoms
Study of HS-10384 in Participants of Chinese Postmenopausal Women
A randomized, double-blind, placebo-controlled phase Ib clinical study to evaluate the safety, tolerability and pharmacokinetics characteristics of HS-10384 in Chinese postmenopausal women.
- Trial name
- NCT06122181
- Testing
- HS-10384 tablets
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Hansoh BioMedical R&D Company
Postmenopause
Efficacy and Tolerability of Angeliq in Thai Women
To evaluate the safety, tolerability, and efficacy of Angeliq in Thai post menopausal women with hot flushes and other climacteric symptoms.
- Trial name
- NCT00185328
- Testing
- Estradiol/DRSP (Angeliq, BAY86-4891)
- Volunteers
- 55 people
- Sponsor
- Bayer
Postmenopausal Symptoms
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
The purpose of this study is to assess the safety \& efficacy of Brisdelle (paroxetine mesylate) Capsules 7.5 mg for treatment of vasomotor symptoms (VMS) associated with menopause.
- Trial name
- N30-003 (NCT01361308)
- Testing
- Brisdelle (paroxetine mesylate)
- Where
- 74 sites in United States
- Volunteers
- 614 people
- Sponsor
- Noven Therapeutics
Menopause, Hot Flashes
A Double-Blind Study to Evaluate the Effect of Femarelle® on Menopausal on Vasomotor Symptoms
The purpose of this study is to test the effects of Femarelle ( a plan-derived SERM) on hot flushes and quality of life in menopausal women.
- Trial name
- NCT01063725
- Testing
- Femarelle
- Where
- 5 sites in Israel
- Volunteers
- 200 people
- Sponsor
- Se-cure Pharmaceuticals Ltd.
Vasomotor Symptoms, Adult Healthy Volunteers
A Study to Assess Safety and Tolerability of GS1-144 in Healthy Volunteers
The primary purpose of this study is to assess the safety and tolerability of single ascending doses of GS1-144 in healthy participants in Part 1 and to assess the safety and tolerability of multiple ascending doses of GS1-144 in…
- Trial name
- NCT06204250
- Testing
- GS1-144
- Where
- Australia
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Perimenopause, Perimenopausal Depression
A Trial to Investigate the Accuracy of a Wearable Device in Collecting Data Related to Perimenopausal Symptoms in Women
The goal of this observational study is to investigate the accuracy of the device in characterizing perimenopausal and menopausal symptoms including vasomotor symptoms, anxiety, sleep quality compared to self-reported symptoms…
- Conditions
- Perimenopause, Perimenopausal Depression, Perimenopausal Insomnia, Perimenopausal Women
- Trial name
- NCT07022925
- Where
- Canada
- Volunteers
- 110 people
- Sponsor
- IdentifyHer Limited
Postmenopause
Study Evaluating Estradiol/Trimegestone in Vasomotor Symptoms (VMS) in Post-Menopausal Women.
The purpose of this study is to evaluate vasomotor symptoms (VMS) control of the continuous regimen 17 b estradiol/trimegestone combination.
- Trial name
- NCT00195455
- Testing
- Trimegestone, 17b Estradiol
- Where
- 6 sites in Mexico
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Hot Flashes
A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause
This study was for women in menopause with hot flashes. Menopause, a normal part of aging, was the time of a woman's last period. Hot flashes can interrupt a woman's daily life.
- Trial name
- Skylight 4 (NCT04003389)
- Testing
- fezolinetant
- Where
- 182 sites in United States, Canada and 6 more
- Volunteers
- 1,831 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Vasomotor Syndrome
Clinical Study to Evaluate the Efficacy and Safety of GS1-144 Tablets in the Treatment of Moderate to Severe Vasomotor Symptoms in Chinese Postmenopausal Women.
A Randomized, Double-blind, Placebo-controlled, Parallel-group Phase II Clinical Study to Evaluate the Efficacy and Safety of GS1-144 Tablets in the Treatment of Moderate to Severe Vasomotor Symptoms in Chinese Postmenopausal…
- Trial name
- NCT06726850
- Testing
- GS1-144
- Where
- China
- Volunteers
- 129 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Depression, Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women
Desvenlafaxine succinate (DVS) is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI). The sustained-release (SR) formulation, DVS SR, is being studied in the development program for the treatment of…
- Conditions
- Depression, Depressive Disorder, Depressive Disorder, Major
- Trial name
- NCT00369343
- Testing
- Desvenlafaxine administered as a succinate salt in a sustained-release form (DVS SR)
- Where
- 37 sites in United States
- Volunteers
- 381 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Vasomotor Symptoms, Hot Flushes
Dehydroepiandrosterone (DHEA) + Acolbifene Against Vasomotor Symptoms (Hot Flushes) in Postmenopausal Women
The purpose of this Phase III trial is to evaluate the efficacy of oral administration of dehydroepiandrosterone (DHEA) combined with acolbifene (a selective estrogen receptor modulator (SERM)) on vasomotor symptoms (hot flushes)…
- Trial name
- NCT01452373
- Testing
- DHEA and Acolbifene
- Where
- 15 sites in Canada
- Volunteers
- 238 people
- Sponsor
- EndoCeutics Inc.